# US 2023/0265483 A1 · Methods for testing andexanet potency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265483 A1
- Document ID: US20230265483A1
- Status: Published application
- Kind: A1
- Application number: 18/010,076
- Filed: 2021-06-10
- Published: 2023-08-24
- Earliest claimed: 2020-06-16
- Assignees: Alexion Pharmaceuticals, Inc.
- Applicants: Alexion Pharmaceuticals, Inc.
- Inventors: Joel Freeberg; Genmin Lu; Pamela Conley
- Web page: https://patentgrep.com/patent/US20230265483A1

## CPC

- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/52: Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper {and including single- and multilayer analytical elements (immunological elements G01N33/54386; involving labelled immunochemicals G01N33/58; for haemoglobin or occult blood G01N33/72)}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2333/96411: Serine endopeptidases (3.4.21)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates kits and methods for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of a wild-type factor Xa.

## Claims

### Claim 1

A method for determining the activity of an andexanet sample, comprising:
admixing a test sample comprising andexanet with a mixture comprising a human factor Xa (HFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of the fXa to the fXa inhibitor is from 0.2:1 to 0.3:1;
adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate is able to release a chromophore upon reaction with the HFXa;
detecting the amount of released chromophore; and
calculating, from the amount of the released chromophore, the activity of the andexanet sample in releasing the HFXa from the direct fXa inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the molar ratio of the HFXa to the fXa inhibitor is from 0.22 to 0.28.

### Claim 3 (depends on 1)

The method of claim 1, wherein the molar ratio of the HFXa to the fXa inhibitor is from 0.24 to 0.26.

### Claim 4

The method of any preceding claim, wherein the HFXa, after the test sample is added, has a concentration of about 8 to 14 nM.

### Claim 5 (depends on 4)

The method of claim 4, wherein the HFXa, after the test sample is added, has a concentration of about 10 to 12 nM.

### Claim 6

The method of any preceding claim, wherein the direct fXa inhibitor is selected from the group consisting of betrixaban, apixaban, rivaroxaban, edoxaban, otamixaban, letaxaban and eribaxaban.

### Claim 7 (depends on 6)

The method of claim 6, wherein the direct fXa inhibitor is betrixaban.

### Claim 8

The method of any preceding claim, wherein the chromogenic fXa substrate is spectrozyme-Xa.

### Claim 9

The method of any preceding claim, further comprising validating the activity of the andexanet sample with a standard curve generated with a reference andexanet sample.

### Claim 10

A method for determining the activity of an andexanet sample, comprising:
admixing a test sample comprising andexanet with a mixture comprising a bovine factor Xa (BFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of the BFXa to the fXa inhibitor is from 0.15:1 to 0.25:1;
adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate is able to release a chromophore upon reaction with the BFXa;
detecting the amount of released chromophore; and
calculating, from the amount of the released chromophore, the activity of the andexanet sample in releasing the BFXa from the direct fXa inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the molar ratio of the BFXa to the fXa inhibitor is from 0.16 to 0.20.

### Claim 12 (depends on 10)

The method of claim 10, wherein the molar ratio of the BFXa to the fXa inhibitor is from 0.17 to 0.19.

### Claim 13 (depends on 10, 11, 12)

The method of any one of claims 10-12, wherein the BFXa, after the test sample is added, has a concentration of about 10 to 20 nM.

### Claim 14 (depends on 13)

The method of claim 13, wherein the BFXa, after the test sample is added, has a concentration of about 14 to 18 nM.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The method of any one of claims 10-14, wherein the direct fXa inhibitor is selected from the group consisting of betrixaban, apixaban, rivaroxaban, edoxaban, otamixaban, letaxaban and eribaxaban.

### Claim 16 (depends on 15)

The method of claim 15, wherein the direct fXa inhibitor is betrixaban.

### Claim 17 (depends on 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 10-16, wherein the chromogenic fXa substrate is Spectrozyme-Xa.
